Trending: Sanofi's Notus Trial Meets Primary Endpoint
27 Noviembre 2023 - 9:31AM
Noticias Dow Jones
10:01 ET -- Sanofi is one of the most mentioned companies in the
U.S. across all news items in the last 12 hours, according to
Factiva data. Sanofi said a second phase 3 trial of Dupixent met
its primary endpoint with what the company said was overwhelming
efficacy. Sanofi said its Notus trial confirmed positive published
results from the Phase 3 Boreas trial. The Notus trial found that
the treatment "significantly reduced exacerbations," and that
treatment with Dupixent led to rapid and significant improvements
in lung function for patients with the life-threatening respiratory
disease COPD. Dow Jones & Co. owns Factiva.
(chris.wack@wsj.com)
(END) Dow Jones Newswires
November 27, 2023 10:16 ET (15:16 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Sanofi (NASDAQ:SNY)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Sanofi (NASDAQ:SNY)
Gráfica de Acción Histórica
De May 2023 a May 2024